Making sense of posaconazole therapeutic drug monitoring

A practical approach

Michelle R. Ananda-Rajah, Andrew P Grigg, Monica Slavin

    Research output: Contribution to journalReview ArticleResearchpeer-review

    23 Citations (Scopus)

    Abstract

    PURPOSE OF REVIEW: Therapeutic drug monitoring (TDM) may be an important adjunct to optimizing the use of posaconazole. RECENT FINDINGS: Limited clinical studies suggest that an exposure-response relationship for posaconazole exists for the treatment of established invasive fungal diseases (IFDs), with emerging but less compelling data supporting its role in prophylaxis. The high prevalence of subtherapeutic levels has not translated to high prophylactic failure rates perhaps because of preferential uptake by effector cells important in the front-line defence against Aspergillus species. Nevertheless, TDM would appear prudent in patients deemed at highest risk for IFD with correction of patient modifiable factors and attention to drug administration important in optimizing drug exposure. TDM performed within a few days after commencing posaconazole may be predictive of steady-state levels, thus minimizing the delay in obtaining results in addition to identifying a subset of patients who may remain persistently subtherapeutic and also resistant to dose-escalation. Trough levels may be supplanted by untimed levels at steady state, thereby expanding the practicalities of TDM. We propose that TDM becomes one of the several measures in an integrated approach to IFD prevention combining screening of high-risk haematology patients for invasive aspergillosis at presentation, together with prospective surveillance for IFD, explicit criteria for switching to an alternative prophylactic agent and adherence to infection control practices. SUMMARY: Growing evidence supports the value of TDM for posaconazole to identify patients who may benefit from correction of modifiable factors impacting bioavailability, dosage adjustment or switch to an alternative agent.

    Original languageEnglish
    Pages (from-to)605-611
    Number of pages7
    JournalCurrent Opinion in Infectious Diseases
    Volume25
    Issue number6
    DOIs
    Publication statusPublished - Dec 2012

    Keywords

    • antifungal
    • fungal infections
    • posaconazole
    • therapeutic drug monitoring

    Cite this

    @article{132b2e0c5d104d90ab726f6343813379,
    title = "Making sense of posaconazole therapeutic drug monitoring: A practical approach",
    abstract = "PURPOSE OF REVIEW: Therapeutic drug monitoring (TDM) may be an important adjunct to optimizing the use of posaconazole. RECENT FINDINGS: Limited clinical studies suggest that an exposure-response relationship for posaconazole exists for the treatment of established invasive fungal diseases (IFDs), with emerging but less compelling data supporting its role in prophylaxis. The high prevalence of subtherapeutic levels has not translated to high prophylactic failure rates perhaps because of preferential uptake by effector cells important in the front-line defence against Aspergillus species. Nevertheless, TDM would appear prudent in patients deemed at highest risk for IFD with correction of patient modifiable factors and attention to drug administration important in optimizing drug exposure. TDM performed within a few days after commencing posaconazole may be predictive of steady-state levels, thus minimizing the delay in obtaining results in addition to identifying a subset of patients who may remain persistently subtherapeutic and also resistant to dose-escalation. Trough levels may be supplanted by untimed levels at steady state, thereby expanding the practicalities of TDM. We propose that TDM becomes one of the several measures in an integrated approach to IFD prevention combining screening of high-risk haematology patients for invasive aspergillosis at presentation, together with prospective surveillance for IFD, explicit criteria for switching to an alternative prophylactic agent and adherence to infection control practices. SUMMARY: Growing evidence supports the value of TDM for posaconazole to identify patients who may benefit from correction of modifiable factors impacting bioavailability, dosage adjustment or switch to an alternative agent.",
    keywords = "antifungal, fungal infections, posaconazole, therapeutic drug monitoring",
    author = "Ananda-Rajah, {Michelle R.} and Grigg, {Andrew P} and Monica Slavin",
    year = "2012",
    month = "12",
    doi = "10.1097/QCO.0b013e328359a56e",
    language = "English",
    volume = "25",
    pages = "605--611",
    journal = "Current Opinion in Infectious Diseases",
    issn = "0951-7375",
    publisher = "Lippincott Williams & Wilkins",
    number = "6",

    }

    Making sense of posaconazole therapeutic drug monitoring : A practical approach. / Ananda-Rajah, Michelle R.; Grigg, Andrew P; Slavin, Monica.

    In: Current Opinion in Infectious Diseases, Vol. 25, No. 6, 12.2012, p. 605-611.

    Research output: Contribution to journalReview ArticleResearchpeer-review

    TY - JOUR

    T1 - Making sense of posaconazole therapeutic drug monitoring

    T2 - A practical approach

    AU - Ananda-Rajah, Michelle R.

    AU - Grigg, Andrew P

    AU - Slavin, Monica

    PY - 2012/12

    Y1 - 2012/12

    N2 - PURPOSE OF REVIEW: Therapeutic drug monitoring (TDM) may be an important adjunct to optimizing the use of posaconazole. RECENT FINDINGS: Limited clinical studies suggest that an exposure-response relationship for posaconazole exists for the treatment of established invasive fungal diseases (IFDs), with emerging but less compelling data supporting its role in prophylaxis. The high prevalence of subtherapeutic levels has not translated to high prophylactic failure rates perhaps because of preferential uptake by effector cells important in the front-line defence against Aspergillus species. Nevertheless, TDM would appear prudent in patients deemed at highest risk for IFD with correction of patient modifiable factors and attention to drug administration important in optimizing drug exposure. TDM performed within a few days after commencing posaconazole may be predictive of steady-state levels, thus minimizing the delay in obtaining results in addition to identifying a subset of patients who may remain persistently subtherapeutic and also resistant to dose-escalation. Trough levels may be supplanted by untimed levels at steady state, thereby expanding the practicalities of TDM. We propose that TDM becomes one of the several measures in an integrated approach to IFD prevention combining screening of high-risk haematology patients for invasive aspergillosis at presentation, together with prospective surveillance for IFD, explicit criteria for switching to an alternative prophylactic agent and adherence to infection control practices. SUMMARY: Growing evidence supports the value of TDM for posaconazole to identify patients who may benefit from correction of modifiable factors impacting bioavailability, dosage adjustment or switch to an alternative agent.

    AB - PURPOSE OF REVIEW: Therapeutic drug monitoring (TDM) may be an important adjunct to optimizing the use of posaconazole. RECENT FINDINGS: Limited clinical studies suggest that an exposure-response relationship for posaconazole exists for the treatment of established invasive fungal diseases (IFDs), with emerging but less compelling data supporting its role in prophylaxis. The high prevalence of subtherapeutic levels has not translated to high prophylactic failure rates perhaps because of preferential uptake by effector cells important in the front-line defence against Aspergillus species. Nevertheless, TDM would appear prudent in patients deemed at highest risk for IFD with correction of patient modifiable factors and attention to drug administration important in optimizing drug exposure. TDM performed within a few days after commencing posaconazole may be predictive of steady-state levels, thus minimizing the delay in obtaining results in addition to identifying a subset of patients who may remain persistently subtherapeutic and also resistant to dose-escalation. Trough levels may be supplanted by untimed levels at steady state, thereby expanding the practicalities of TDM. We propose that TDM becomes one of the several measures in an integrated approach to IFD prevention combining screening of high-risk haematology patients for invasive aspergillosis at presentation, together with prospective surveillance for IFD, explicit criteria for switching to an alternative prophylactic agent and adherence to infection control practices. SUMMARY: Growing evidence supports the value of TDM for posaconazole to identify patients who may benefit from correction of modifiable factors impacting bioavailability, dosage adjustment or switch to an alternative agent.

    KW - antifungal

    KW - fungal infections

    KW - posaconazole

    KW - therapeutic drug monitoring

    UR - http://www.scopus.com/inward/record.url?scp=84870064899&partnerID=8YFLogxK

    U2 - 10.1097/QCO.0b013e328359a56e

    DO - 10.1097/QCO.0b013e328359a56e

    M3 - Review Article

    VL - 25

    SP - 605

    EP - 611

    JO - Current Opinion in Infectious Diseases

    JF - Current Opinion in Infectious Diseases

    SN - 0951-7375

    IS - 6

    ER -